In recent trading session, Humacyte Inc (NASDAQ:HUMA) saw 0.76 million shares changing hands at last check today with its beta currently measuring 1.62. Company’s recent per share price level of $1.39 trading at -$0.07 or -4.80% at last check today assigns it a market valuation of $215.60M. That most recent trading price of HUMA’s stock is at a discount of -617.27% from its 52-week high price of $9.97 and is indicating a premium of 6.47% from its 52-week low price of $1.30. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 8.8 million shares which gives us an average trading volume of 3.29 million if we extend that period to 3-months.
For Humacyte Inc (HUMA), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.29. Splitting up the data highlights that, out of 2 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 1 suggested the stock as a Hold whereas 1 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -0.21 in the current quarter.
Humacyte Inc (NASDAQ:HUMA) trade information
Upright in the red during last session for losing -4.80%, in the last five days HUMA remained trading in the red while hitting it’s week-highest on Friday, 03/28/25 when the stock touched $1.39 price level, adding 34.74% to its value on the day. Humacyte Inc’s shares saw a change of -72.48% in year-to-date performance and have moved -30.85% in past 5-day. Humacyte Inc (NASDAQ:HUMA) showed a performance of -55.88% in past 30-days. Number of shares sold short was 26.6 million shares which calculate 11.69 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of 8 to the stock, which implies a rise of 82.62% to its recent value today. Analysts have been projecting 6 as a low price target for the stock while placing it at a high target of 10. It follows that stock’s current price would drop -331.65% in reaching the projected high whereas dropping to the targeted low would mean a loss of -331.65% for stock’s current value.
Humacyte Inc (HUMA) estimates and forecasts
5 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of 457.8k for the same. And 5 analysts are in estimates of company making revenue of 1.17M in the next quarter. Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 42.43% during past 5 years.
Humacyte Inc (NASDAQ:HUMA)’s Major holders
Insiders are in possession of 21.25% of company’s total shares while institution are holding 27.45 percent of that, with stock having share float percentage of 34.85%. Investors also watch the number of corporate investors in a company very closely, which is 27.45% institutions for Humacyte Inc that are currently holding shares of the company. BLACKROCK INC. is the top institutional holder at HUMA for having 7.14 million shares of worth $34.27 million. And as of 2024-06-30, it was holding 5.9912 of the company’s outstanding shares.
The second largest institutional holder is VANGUARD GROUP INC, which was holding about 4.73 million shares on 2024-06-30. The number of shares represents firm’s hold over 4.3693 of outstanding shares, having a total worth of $22.7 million.
On the other hand, VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and SPDR SERIES TRUST-SPDR(R) S&P(R) Biotech ETF are the top two Mutual Funds which own company’s shares. As of Dec 31, 2024, the former fund manager was holding 2.59 shares of worth $3.59 million or 1.79% of the total outstanding shares. The later fund manager was in possession of 2.45 shares on Feb 28, 2025, making its stake of worth around $3.4 million in the company or a holder of 1.69% of company’s stock.
